Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$41.22 USD

41.22
2,409,519

+0.04 (0.10%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $41.20 -0.02 (-0.05%) 6:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline

by Zacks Equity Research

Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.

Kinjel Shah headshot

Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV

by Kinjel Shah

Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.

Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised

by Zacks Equity Research

Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.

Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track

by Zacks Equity Research

Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

Glaxo (GSK) Beats Earnings and Revenues Estimates in Q2

by Zacks Equity Research

Glaxo (GSK) beats earnings as well as revenues estimates in the second quarter of 2021. Stock up.

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

by Zacks Equity Research

Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.

Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan

by Zacks Equity Research

Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.

Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance

by Zacks Equity Research

Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above market. Market recovery might have led to continued recovery in Medical Devices segment in the second quarter.

Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study

by Zacks Equity Research

Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.

Lilly (LLY) Stock Riding on Pipeline Developments This Year

by Zacks Equity Research

Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.

Kinjel Shah headshot

Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates

by Kinjel Shah

Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)

Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.

Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More

by Zacks Equity Research

The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).

Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer

by Zacks Equity Research

Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

by Zacks Equity Research

Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.

Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

by Zacks Equity Research

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda

by Zacks Equity Research

Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.

CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study

by Zacks Equity Research

CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.

Kinjel Shah headshot

3 Big Drugmakers Likely to be in Focus in Second Half of 2021

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.

Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study

Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study

Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study

by Zacks Equity Research

Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.